Polymyxin B

Eurosets and Estor announce a strategic partnership for the exclusive distribution of Polymyxin B hemoperfusion therapy in France, Belgium, Netherlands, Luxemburg and Austria

Retrieved on: 
Friday, April 28, 2023

This strategic alliance between Eurosets and Estor will further contribute to the advancement of Polymyxin B hemoperfusion therapy, both in the area of post-cardiac surgery and in the general intensive care itself, so that Polymyxin B hemoperfusion can be available to a larger patient population in Europe.

Key Points: 
  • This strategic alliance between Eurosets and Estor will further contribute to the advancement of Polymyxin B hemoperfusion therapy, both in the area of post-cardiac surgery and in the general intensive care itself, so that Polymyxin B hemoperfusion can be available to a larger patient population in Europe.
  • Polymyxin B hemoperfusion is the reference complementary therapy for neutralizing endotoxin in human blood, combining the unique properties of Polymyxin B and blood purification therapy.
  • More than 250,000 patients have been treated with Polymyxin B hemoperfusion therapy worldwide and more than 400 peer-reviewed articles are available in the literature.
  • “This strategic alliance between Eurosets and Estor represents a milestone that will contribute further to Polymyxin B hemoperfusion advancement in post-cardiac surgery and general intensive care for the benefit of patients in Europe,” said Dr. Mattia Corrado Bellaviti, CEO Estor.

Global Burn Ointment Market (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 19, 2022

The topical antibiotics segment is expected to hold a significant market share during the forecast period.

Key Points: 
  • The topical antibiotics segment is expected to hold a significant market share during the forecast period.
  • The major factors propelling the growth of this segment include the high acceptance of burn ointment products in home-care settings and the rising incidence of burns across the globe.
  • Mafenide acetate, Bacitracin, Mupirocin, Neosporin, Polymyxin B, Nitrofurazone, and Nystatin are the widely accepted topical antibiotics burn ointments.
  • As per the Royal Australian College of General Practitioners 2017 report, stated burn injuries are common and costly.

Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens

Retrieved on: 
Wednesday, March 30, 2022

Qpex Biopharma, Inc. , (Qpex) an antibiotic resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced research published in Nature Communications on the discovery and preclinical properties of QPX9003, a new synthetic lipopeptide antibiotic that is distinct from existing polymyxin-type antibiotics.

Key Points: 
  • Qpex Biopharma, Inc. , (Qpex) an antibiotic resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced research published in Nature Communications on the discovery and preclinical properties of QPX9003, a new synthetic lipopeptide antibiotic that is distinct from existing polymyxin-type antibiotics.
  • The resulting new lipopeptide QPX9003 is pharmacologically distinct from existing polymyxin drugs with a superior safety and efficacy against experimentally-induced lung infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae.
  • Our scientists have gained unique insights into the pharmacological properties of polymyxin antibiotics that informed our strategy on how to innovate a new lipopeptide class of antibiotics.
  • QPX9003: a next-generation, IV-administered synthetic lipopeptide with an enhanced therapeutic profile designed to address drug-resistant infections caused by Pseudomonas and Acinetobacter.

Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial

Retrieved on: 
Monday, October 18, 2021

ATTACK was a landmark clinical trial, the first to successfully evaluate an investigational agent targeting a specific drug-resistant Gram-negative pathogen.

Key Points: 
  • ATTACK was a landmark clinical trial, the first to successfully evaluate an investigational agent targeting a specific drug-resistant Gram-negative pathogen.
  • The positive outcome of the ATTACK trial is the culmination of a tremendous effort by our team, and a major milestone for Entasis.
  • The data from the ATTACK trial are robust and incredibly exciting, demonstrating positive safety and efficacy results, combined with favorable and meaningful clinical cure rates.
  • The global Phase3 registrational ATTACK trial was initiated in April 2019 with positive Phase 3 topline data announced in October 2021.

Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment

Retrieved on: 
Monday, June 22, 2020

LAKE FOREST, Ill., June 22, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc.(OTC Pink Market: AKRXQ), a leading specialty generic pharmaceutical company, today announced the launch of its Abbreviated New Animal Drug Application (ANADA) for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP (BNP).

Key Points: 
  • LAKE FOREST, Ill., June 22, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc.(OTC Pink Market: AKRXQ), a leading specialty generic pharmaceutical company, today announced the launch of its Abbreviated New Animal Drug Application (ANADA) for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP (BNP).
  • Douglas Boothe, Akorns President and Chief Executive Officer, stated, This is an important launch for veterinarians and Akorn as there has been a shortage in the market for veterinary approved ophthalmics.
  • We are pleased that our distributor partners will have BNP commercially available in both distributor and Akorn labels.
  • Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP is indicated for the treatment of superficial bacterial infections of the eyelid and conjunctiva of dogs and cats when due to organisms susceptible to one or more of the antibiotics contained in the ointment.